These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8557572)

  • 1. Structure determination of ribosylated rifampicin and its derivative: new inactivated metabolites of rifampicin by mycobacterial strains.
    Morisaki N; Kobayashi H; Iwasaki S; Furihata K; Dabbs ER; Yazawa K; Mikami Y
    J Antibiot (Tokyo); 1995 Nov; 48(11):1299-303. PubMed ID: 8557572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structures of ADP-ribosylated rifampicin and its metabolite: intermediates of rifampicin-ribosylation by Mycobacterium smegmatis DSM43756.
    Morisaki N; Hashimoto Y; Furihata K; Imai T; Watanabe K; Mikami Y; Yazawa K; Ando A; Nagata Y; Dabbs ER
    J Antibiot (Tokyo); 2000 Mar; 53(3):269-75. PubMed ID: 10819298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivated products of rifampicin by pathogenic Nocardia spp.: structures of glycosylated and phosphorylated metabolites of rifampicin and 3-formylrifamycin SV.
    Morisaki N; Iwasaki S; Yazawa K; Mikami Y; Maeda A
    J Antibiot (Tokyo); 1993 Oct; 46(10):1605-10. PubMed ID: 8244890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and characterization of a new intermediate in the ribosylative inactivation pathway of rifampin by Mycobacterium smegmatis.
    Imai T; Watanabe K; Mikami Y; Yazawa K; Ando A; Nagata Y; Morisaki N; Hashimoto Y; Furihata K; Dabbs ER
    Microb Drug Resist; 1999; 5(4):259-64. PubMed ID: 10647083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphorylative inactivation of rifampicin by Nocardia otitidiscaviarum.
    Yazawa K; Mikami Y; Maeda A; Morisaki N; Iwasaki S
    J Antimicrob Chemother; 1994 Jun; 33(6):1127-35. PubMed ID: 7928806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ADP-ribosylation as an intermediate step in inactivation of rifampin by a mycobacterial gene.
    Quan S; Imai T; Mikami Y; Yazawa K; Dabbs ER; Morisaki N; Iwasaki S; Hashimoto Y; Furihata K
    Antimicrob Agents Chemother; 1999 Jan; 43(1):181-4. PubMed ID: 9869590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ribosylation by mycobacterial strains as a new mechanism of rifampin inactivation.
    Dabbs ER; Yazawa K; Mikami Y; Miyaji M; Morisaki N; Iwasaki S; Furihata K
    Antimicrob Agents Chemother; 1995 Apr; 39(4):1007-9. PubMed ID: 7785970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Light inhibits rifampicin inactivation and reduces rifampicin resistance due to a cloned mycobacterial ADP-ribosylation gene.
    Dabbs ER; Quan S
    FEMS Microbiol Lett; 2000 Jan; 182(1):105-9. PubMed ID: 10612740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accumulation of rifampicin by Mycobacterium aurum, Mycobacterium smegmatis and Mycobacterium tuberculosis.
    Piddock LJ; Williams KJ; Ricci V
    J Antimicrob Chemother; 2000 Feb; 45(2):159-65. PubMed ID: 10660497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactive rifampicin derivative able to damage transcription complex.
    Kozlov M; Nudler E; Nikiforov V; Mustaev A
    Bioconjug Chem; 2013 Mar; 24(3):443-7. PubMed ID: 23425196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modification of rifamycin polyketide backbone leads to improved drug activity against rifampicin-resistant Mycobacterium tuberculosis.
    Nigam A; Almabruk KH; Saxena A; Yang J; Mukherjee U; Kaur H; Kohli P; Kumari R; Singh P; Zakharov LN; Singh Y; Mahmud T; Lal R
    J Biol Chem; 2014 Jul; 289(30):21142-52. PubMed ID: 24923585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative in vitro activities of rifamycin analogues against Mycobacterium leprae.
    Dhople AM
    Indian J Lepr; 1997; 69(4):377-84. PubMed ID: 9474513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of rifampicin as a new anti-glycating compound by matrix-assisted laser desorption/ionization mass spectrometry-based insulin glycation assay.
    Golegaonkar SB; Bhonsle HS; Boppana R; Kulkarni MJ
    Eur J Mass Spectrom (Chichester); 2010; 16(2):221-6. PubMed ID: 20212331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The incorporation of rifampicin into multilayer and monolayer vesicles (liposomes) of different phosholipid composition].
    Minina AS; Sorokoumova GM; Selishcheva AA; Malikova NM; Kalashnikova TIu; Shvets VI
    Biofizika; 2004; 49(4):674-9. PubMed ID: 15458251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG.
    Rastogi N; Goh KS; Berchel M; Bryskier A
    J Antimicrob Chemother; 2000 Oct; 46(4):565-70. PubMed ID: 11020253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ribosylative inactivation of rifampin by Mycobacterium smegmatis is a principal contributor to its low susceptibility to this antibiotic.
    Quan S; Venter H; Dabbs ER
    Antimicrob Agents Chemother; 1997 Nov; 41(11):2456-60. PubMed ID: 9371349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biowaiver monographs for immediate release solid oral dosage forms: rifampicin.
    Becker C; Dressman JB; Junginger HE; Kopp S; Midha KK; Shah VP; Stavchansky S; Barends DM
    J Pharm Sci; 2009 Jul; 98(7):2252-67. PubMed ID: 19160441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of rifampicin and isoniazid with large unilamellar liposomes: spectroscopic location studies.
    Rodrigues C; Gameiro P; Prieto M; de Castro B
    Biochim Biophys Acta; 2003 Mar; 1620(1-3):151-9. PubMed ID: 12595084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LC-MS/TOF and UHPLC-MS/MS study of in vivo fate of rifamycin isonicotinyl hydrazone formed on oral co-administration of rifampicin and isoniazid.
    Prasad B; Singh S
    J Pharm Biomed Anal; 2010 Jul; 52(3):377-83. PubMed ID: 19692195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of pH, mucin and bovine serum on rifampicin permeability through Caco-2 cells.
    Gonçalves JE; Ballerini Fernandes M; Chiann C; Gai MN; De Souza J; Storpirtis S
    Biopharm Drug Dispos; 2012 Sep; 33(6):316-23. PubMed ID: 22847250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.